 | Up a level |
Davies, Andrew J; Barrans, Sharon; Stanton, Louise; Caddy, Josh; Wilding, Sam; Saunders, Geoff; Mamot, Christoph; Novak, Urban; McMillan, Andrew; Fields, Paul; Collins, Graham P; Stephens, Richard; Cucco, Francesco; Sha, Chulin; van Hoppe, Moniek; Tooze, Reuben; Davies, John R; Griffiths, Gareth; Schuh, Anna; Burton, Catherine; ... (2023). Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(15), pp. 2718-2723. American Society of Clinical Oncology 10.1200/JCO.23.00033
Davies, Andrew; Cummin, Thomas E; Barrans, Sharon; Maishman, Tom; Mamot, Christoph; Novak, Urban; Caddy, Josh; Stanton, Louise; Kazmi-Stokes, Shamim; McMillan, Andrew; Fields, Paul; Pocock, Christopher; Collins, Graham P; Stephens, Richard; Cucco, Francesco; Clipson, Alexandra; Sha, Chulin; Tooze, Reuben; Care, Matthew A; Griffiths, Gareth; ... (2019). Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. The lancet oncology, 20(5), pp. 649-662. Elsevier 10.1016/S1470-2045(18)30935-5
